Search Results for: MSD
Deals Orna Therapeutics
Orna Therapeutics Secures Multi-Billion RNA Deal With Merck After $221 Million Series B
2022-08-17
Deals Alzheimer's Disease
Merck Dangles $1.1 Billion For Cerevance To Discover New Targets For Alzheimer’s
2022-08-10
Trials & Approvals Liver Cancer
Merck and Eisai Come Up Short in the Clinic with Liver Cancer Combination Therapy
2022-08-04
Licensing Merck
Oncology Research Collaboration between Kelun-Biotech and MSD
2022-07-27
Trials & Approvals Pneumococcal Vaccine
FDA Blesses Merck’s Pneumococcal Vaccine for Pediatric Use
2022-06-23
Trials & Approvals Merck
EU Expands Merck’s Keytruda Use on Breast Cancer
2022-05-25
COVID-19 Antiviral Treatment
Pfizer to Address COVID-19 Reinfection After Paxlovid Treatment
2022-05-19
Deals AstraZeneca
AstraZeneca Taps China’s AmoyDx for Companion Diagnostics
2022-04-19
Deals SK Biopharmaceuticals
SK Biopharma Teams Up with Targeted Protein Degrader Ubix
2022-04-15
AACR 2022: Ascentage Pharma Presents Latest Results from Six Preclinical Studies
2022-04-13
COVID-19 Oral Drug
EUA of Monoclonal Antibodies Revoked: Are Oral COVID Drugs the Only Hope?
2022-04-06
R&D Immunotherapy
Roche’s Phase III Trial of ES-SCLC Immunotherapy Fails to Extend Progression-Free Survival
2022-04-05
COVID-19 COVID-19 Treatment
The Absence of Long COVID Treatment Plans Has Become a New Business Opportunity for Medium-sized Pharmas
2022-03-30
Trials & Approvals
Ascentage Pharma’s MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma
2022-03-21
COVID-19
Joint Fight Against COVID-19, Viva Biotech Contributes to the Production of the Oral COVID-19 Antiviral Medication and Virus Tests
2022-03-18
1 2 3 4 5
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top